Post-earnings recap
Reported
Tue, Aug 11, 2026
EPS actual
$-0.14
EPS est.
$-0.12
EPS surprise
-19.66%
1-day move
+1.05%
Erasca reported a loss per share of $0.14, which was below expectations, but the stock still saw a modest increase of 1.05%. This reaction may indicate that investors are looking beyond the EPS miss, possibly due to other factors not disclosed in the earnings call. Without additional context or guidance, it remains to be seen how the company will perform in the coming quarters.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.14 | N/A | -19.66% |
| Revenue | — | N/A | — |
No transcript is on record for the earnings call, so the analysis is based solely on numerical results.
Erasca, Inc. is a biotechnology company focused on developing therapies for cancer treatment. With a market cap of $6 billion, it operates in the health care sector, which is increasingly important as the demand for innovative medical solutions grows.
Last quarter
In Q1-2026, Erasca reported an EPS of -$0.60, which was significantly below the expected -$0.19. The stock reacted positively, gaining 3.16% the following day despite the miss.
EPS beat streak
0Q
EPS beat rate
63%
Avg EPS surprise
-23.28%
Avg 1-day reaction
+1.03%
Overall, investors are cautious ahead of the earnings report due to the company's recent performance and lack of guidance. The market is watching closely for any signs of improvement.
Bull case
If Erasca can show a significant reduction in losses and progress in its drug pipeline, it could lead to a strong positive reaction from investors.
Bear case
Conversely, if the company reports wider losses and lacks clear future guidance, it may lead to a negative sentiment and a decline in stock price.
The print will turn on these.
Q1
What will the EPS be for Q2-2026?
The EPS figure will be critical in assessing the company's financial health and operational efficiency.
Q2
How much has been invested in R&D this quarter?
Investments in R&D are vital for future growth and innovation, and any changes could signal shifts in strategy.
—
Est. EPS
$0.20
Est. Rev
$609M
Impl. Move
±12.7%
Why consensus could be wrong
The Street may be overly pessimistic about Erasca's ability to control costs and improve its EPS this quarter.
Supporting evidence
Despite a significant EPS miss last quarter, the stock still gained, indicating some investor confidence.
Options pricing suggests a much larger potential move than historical averages, indicating expectations may be misaligned.
The company's focus on R&D may yield unexpected positive results that analysts are not factoring in.
Key risk
If R&D expenses are lower than expected, it could signal better cost management and lead to a positive reassessment.
Pre-commit to what would confirm each case.
The core debate this quarter revolves around whether Erasca can improve its financial performance and maintain its commitment to R&D.
Bull confirmed if
An EPS improvement to -$0.30 or better would confirm the bull case.
Bear confirmed if
An EPS of -$0.70 or worse would confirm the bear case.
What the market is pricing for the move.
Implied Move
±42.13%
Historical Avg
±4.4%
The options market is pricing in a substantial move, indicating that traders expect significant volatility around the earnings report.
Options are pricing ±42.1% while ERAS has averaged ±4.4% over the last 8 prints — setup is pricing rich.
ATM IV
0.9%
30d HV
215.7%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich in Health Care
Fade rate: 13 of 29 (45%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Erasca beats expectations, history suggests a potential stock increase of around 1.65%, confirming a positive outlook.
In line / cautious
If results are in line with expectations, the stock may see muted movement as investors await further clarity.
Miss
If the company misses expectations, history suggests a potential decline of around 7.79%, reflecting ongoing concerns about profitability.
The lines on the call that would change the story.